News
-
2010-06-18
Two new members appointed to LIDDS´ Board
At LIDDS´Annual Meeting in May two new members were appointed to the Board, Michael Oredsson and Jonas Rastad (see more under Company ). Michael Oredsson was also appointed Chairman of the Board. ...
| The Company |
|
|
LIDDS (Local Implant Drug Delivery System) is a Swedish life sciences company developing innovative pharmaceutical products based on its proprietary drug delivery technology. LIDDS was initially founded by researchers and entrepreneurs at Uppsala University, departments of pharmacy and material sciences and University of Gothenburg, departments of urology and oncology, and within the network of P.U.L.S. AB (www.pulsinvest.se), LIDDS is located in Helsingborg, Sweden, in one of Europe’s premiere biotechnology regions.
Liproca® is the first product being developed by LIDDS based on this drug delivery technology. It is a novel product targeted primarily for the treatment of prostate cancer. The purpose is to reduce the side-effects significantly as well as to increase the safety and efficiency relative other current treatment alternatives. The strategic, technological, clinical and pharmaceutical competences to support the comprehensive and focused development of Liproca® are contained within the unique network of LIDDS and PULS. |